MGC Pharma receives patent protection for epilepsy drug

pharmafile | May 10, 2022 | News story | Manufacturing and Production  

MGC Pharmaceuticals said a patent had been granted, protecting its unique system used to deliver a cannabis-derived drug being developed to combat hard-to-treat forms of epilepsy, according to Proactive Investors.

The Slovenian Intellectual Property Office has not provided sign-off for CannEpil, which uses a self-nano emulsifying technology to carry the company’s high CBD, low THC medicinal compound.

CannEpil is one of four products approved for use in the Republic of Ireland, and prescribed to 300-400 people both in the Republic and in Australia.

“We are very pleased that the patent for our proprietary drug delivery system has now been granted by the Slovenian Intellectual Property Office,” said MGC’s managing director and co-founder, Roby Zomer.

“This is a recognition of the strength of our product and provides legal commercial protection for our company and our partner’s IP.”

Epilepsy is a neurological disorder that causes seizures or unusual sensations and behaviours, caused by excessive electrical activity within networks of neurons in the brain. The disorder affects around 600,000 people in the UK, and 50 million worldwide. A third of adults, and up to a quarter of children, suffer from the refractory, or hard-to-treat form of the condition, which is targeted by CannEpil.

Is 2021, CannEpil was made available for free under the Irish healthcare system to patients with refractory epilepsy for the first time.

MGC Pharma was founded in 2015, and aims to provide patients with the highest standard of phytomedicines, in order to improve the quality of life for millions across the globe.

Lina Adams

Related Content

No items found

Latest content